Abstract
Combretastatin-A4 phosphate (cis -CA-4) is a tubulin-binding agent currently undergoing clinical trials as an anti-tumour drug. We have investigated whether CA-4 functions as a tumour-specific anti-vascular agent using the hyperplastic thyroid as a novel in vivo model of neovascularization. CA-4 elicited pathological changes in normal tissue, manifested as the induction of multiple, discrete intravascular thrombi. These vascular-damaging effects indicate that CA-4P does not function as a tumour-specific agent but targets neovasculature irrespective of the primary angiogenic stimulus. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE and Brindle KM (1998) Magnetic resonance imaging and spectroscopy of combretastatin A(4) prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 77: 1761–1767
Bedford SB, Quarterman CP, Rathbone DL, Slack JA, Griffin RJ and Stevens MFG (1996) Synthesis of water-soluble prodrugs of the cytotoxic agent combretastatin A4. Bio Med Chem Lett 6: 157–160
Bidey SP, Hill DJ and Eggo MC (1999) Growth factors and goitrogenesis. J Endocrinol 160: 321–332
Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR and Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature. Cancer Res 57: 1829–1834
Griggs J, Metcalfe JC and Hesketh R (2001) Targeting tumour vasculature: the development of Combretastatin A4. The Lancet Oncology 2: 82–87
Grosios K, Holwell SE, McGown AT, Pettit GR and Bibby MC (1999) In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81: 1318–1327
Hanahan D and Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353–364
Hayes AJ, Li LY and Lippman ME (2000) Anti-vascular therapy: a new approach to cancer treatment. Western J Med 172: 39–42
Orsini F, Pelizzoni F, Bellini B and Miglierini G (1997) Synthesis of biologically active polyphenolic glycosides (combretastatin and resveratrol series). Carbohydrate Res 301: 95–109
Peter H, Gerber H, Studer H, Groscurth P and Zakarija M (1991) Comparison of FRTL-5 cell growth in vitro with that of xenotransplanted cells and the thyroid of the recipient mouse. Endocrinology 128: 211–219
Pettit GR and Rhodes MR (1998) Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. Anti-Cancer Drug Design 13: 183–191
Pettit GR, Singh SB, Boyd MR, Hamel E, Pettit RK, Schmidt JM and Hogan F (1995) Antineoplastic agents 291. Isolation and synthesis of combretastatins a-4, a-5, and a-6. J Med Chem 38: 1666–1672
Pettit GR, Rhodes MR, Herald DL, Chaplin DJ, Stratford MRL, Hamel E, Pettit RK, Chapuis JC and Oliva D (1998) Antineoplastic agents 393. Synthesis of the trans -isomer of combretastatin A-4 prodrug. Anti-Cancer Drug Design 13: 981–993
Sato K, Yamazaki K, Shizume KYK, Obara T, Ohsumi K, Demura H, Yamaguchi S and Shibuya M (1995) Stimulation by thyroid-stimulating hormone and Graves’ immunoglobulin G of vascular endothelial growth factor mRNA expression in human follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J Clin Investigation 96: 1295–1302
Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MRL, Dennis MF and Chaplin DJ (1999) Combretastatin A-4 phosphate as a tumour vascular-targeting agent: Early effects in tumours and normal tissues. Cancer Res 59: 1626–1634
Viglietto G, Romano A, Manzo G, Chiappetta G, Paoletti I, Califano D, Galati M, Mauriello V, Bruni P, Laog C, Fusco A and Persico M (1997) Upregulation of the angiogenic factors PIGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggests a TSH-dependent paracrine mechanism for goitre hypervascularisation. Oncogene 15: 2687–2698
Wang J, Milosveski V, Schramek C, Fong G, Becks G and Hill D (1998) Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. J Endocrinol 157: 5–12
Wynford-Thomas D, Stringer B and Williams ED (1982a) Dissociation of growth and function in the rat thyroid during prolonged goitrogen administration. Acta Endocrinol 101: 210–216
Wynford-Thomas D, Stringer B and Williams ED (1982b) Goitrogen induced thyroid growth in the rat: a quantitative morphometric study. Acta Endocrinol 94: 131–140
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Griggs, J., Hesketh, R., Smith, G. et al. Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue. Br J Cancer 84, 832–835 (2001). https://doi.org/10.1054/bjoc.2000.1653
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2000.1653
Keywords
This article is cited by
-
Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent
British Journal of Cancer (2003)
